Benign inverted papillomas have been reported as monoclonal but lacking common genetic alterations identified in squamous cell carcinoma of the head and neck. Epigenetic changes alter the heritable state of gene expression and chromatin organization without change in DNA sequence. We investigated whether epigenetic events of aberrant promoter hypermethylation in genes known to be involved in squamous head and neck cancer underlie the pathogenesis of sinonasal papillomas. Ten formalin-fixed paraffin DNA samples from three inverted papilloma cases, two exophytic (everted) papilloma cases, and two cases with inverted and exophytic components were studied. DNA was obtained from microdissected areas of normal and papilloma areas and examined using a panel of 41 gene probes, designed to interrogate 35 unique genes for aberrant methylation status (22 genes) using the methylation-specific multiplex-ligation-specific polymerase assay. Methylationspecific PCR was employed to confirm aberrant methylation detected by the methylation-specific multiplexligation-specific polymerase assay. All seven cases indicated at least one epigenetic event of aberrant promoter hypermethylation. The CDKN2B gene was a consistent target of aberrant methylation in six of seven cases. Methylation-specific PCR confirmed hypermethylation of CDKN2B. Recurrent biopsies from two inverted papilloma cases had common epigenetic events. Promoter hypermethylation of CDKN2B was a consistent epigenetic event. Common epigenetic alterations in recurrent biopsies underscore a monoclonal origin for these lesions. Epigenetic events contribute to the underlying pathogenesis of benign inverted and exophytic papillomas. As a consistent target of aberrant promoter hypermethylation, CDKN2B may serve as an important epigenetic biomarker for gene reactivation studies.
Sinonasal papillomas have been categorized histologically as inverted, fungiform (exophytic), and cylindrical cell papillomas (also commonly known as oncocytic schneiderian papilloma). 1 Although there is debate about the correct nomenclature, based on the pattern of growth, these papillomas can be grouped as either endophytic (consisting of inverted and cylindrical cell papillomas) or exophytic (fungiform papillomas). Inverted papillomas are the most commonly occurring sinonasal papillomas followed by exophytic. 2 Inverted papillomas arise from the lateral wall of the nose and paranasal sinuses and are associated with invasive squamous cell carcinoma (SCC). Its surface epithelium invaginates into the underlying stroma (Figure 1a ), thus the name inverted (endophytic) papilloma. Exophytic papillomas arise exclusively from the nasal septum. They contain connective tissue stalks producing an everted (exophytic or mushroomshaped) lesion (Figure 1b ). Cylindrical cell papillomas are relatively uncommon, have an inverted growth pattern, mainly arise from the lateral wall of the nose and have higher rates of recurrence and malignant transformation to SCC. Recurrence rates vary widely, ranging from 6 to 33%, despite management by different surgical treatment options. 3 Recurrences are most likely due to incomplete local resection considering that many recur early and at the site of the original tumor. Morphology is not useful in determining if a lesion will recur or acquire malignant changes. A general belief is that once excised, and in the absence of malignancy in the excised specimen, a recurrence is unlikely to convert into malignancy. 4 Search for additional methods to adequately aid in predicting recurrence or malignancy of sinonasal papillomas has clinical utility.
Human papilloma virus (HPV) is frequently associated with nasal papillomas. Studies have found HPV DNA in 50-100% of tested septal (exophytic) papillomas 5 and in 0-86% of lateral wall (inverted) papillomas. 6 Buchwald et al 7 determined that 13% of their cases of SCC associated with inverted papilloma were HPV positive. Most HPV-positive cases of sinonasal papillomas are of the inverted papilloma type. 8 Benign papillomas are preferentially associated with the low-risk HPV types 6 and 11, whereas their malignant counterparts are exclusively positive for HPV-16 DNA. 9 Therefore, HPV infection may be an early event in a multistep process of malignant formation of inverted papillomas. 10 Benign inverted papillomas were reported as monoclonal but lacking common genetic alterations associated with squamous head and neck cancer. 4 Epigenetic changes alter the heritable state of gene expression and chromatin organization without change in DNA sequence. DNA methylation events are increasingly thought of as diagnostic markers for certain tumor types or stages underscoring promoter hypermethylation events as potential epigenetic biomarkers. Loss of p16
INK4a and p15 INK4b protein expression in cancers has been frequently related to DNA hypermethylation. 11 We investigated whether epigenetic events of aberrant promoter hypermethylation in tumor suppressor genes implicated in SCCs of the head and neck underlie the pathogenesis of sinonasal papillomas. A better understanding of these lesions has clinical relevance because they can be predisposed to aggressive local behavior, recurrence, and in rare cases carcinomatous change.
Materials and methods

Papilloma Patient Cohort
The study cohort comprised seven patients with primary and recurrent sinonasal papillomas identified in the Department of Otolaryngology, Henry Ford Health System, between the years of 1996 and 2004. The anatomic locations and histology classification for the cohort are noted in Table 1 . The cohort was followed through September 2006 for further recurrent or progression events. Ten formalin-fixed paraffin DNA samples from seven cases, three inverted, two exophytic and two inverted/ exophytic were examined for promoter hypermethylation by the methylation-specific multiplex-ligation-specific polymerase assay (MS-MLPA). Cases 1 and 2 had recurrent biopsies (Table 1) .
DNA was obtained from microdissected areas of normal and papilloma areas and examined using a panel of 41 gene probes designed to interrogate 35 unique genes (Table 2 ) with known associations to squamous head and neck cancer for aberrant methylation status (22 tumor suppressor genes) employing MS-MLPA, a modification of the conventional MLPA assay. 12 
DNA Extraction
Whole 5 mm tissue sections or microdissected papilloma tissue and adjacent normal when present were processed for DNA extraction as described previously. The standard use of the technique to observe quantitative changes in copy number has been outlined in other studies. [14] [15] [16] [17] Adaptation of the MLPA to detect aberrant methylation (MS-MLPA) has been detailed elsewhere. 12, [18] [19] [20] The probe design is similar to ordinary MLPA probes. For 26/41 probes, the recognition sequence detected by the MLPA probe is contained within a restriction site for the methyl-sensitive enzyme, HhaI ( Figure 2 ). The 41 gene probe panel (Table 2) interrogates 35 unique genes implicated in cancer including HNSCC for losses and gains in a separate reaction in the absence of the methyl-sensitive enzyme HhaI. Because there are two probes each for VHL, CDKN2A, BRCA1, and BRCA2, and three probes for MLH1, a normal control DNA sample will generate 41 individual peaks in the absence of HhaI (Figures 3-5) . A concurrently run reaction with the 41 gene probe set in the presence of HhaI is designed to detect aberrant promoter hypermethylation by taking advantage of a HhaI site in the promoter region of 22 of the 35 unique genes (note that one of the two BRCA1 probes is designed to recognize a region outside the HhaI recognition site, Table 2 ). Fifteen of the 41 gene probes are designed outside an HhaI site and serve as undigested 
Probes with HhaI sites in CpG-rich promoter regions. Genes represented by more than one gene probe. Epigenetic events in sinonasal papillomas JK Stephen et al controls (Figures 3-5 ). Upon digestion of the sample DNA with HhaI, probes that recognize the unmethylated regions will not generate a signal because these sequences have become cut by HhaI and cannot bind to the probe ( Figure 2 ). Conversely, a MLPA probe will bind to an intact methylated site, spared by HhaI, and generate an amplification signal (Figures 2-5 ). Aberrant methylation is identified as the appearance of a signal peak that is otherwise absent in normal DNA samples (Figures 3-5 ). To quantify whether one, both, or more copies of a specific gene locus becomes aberrantly hypermethylated, a Epigenetic events in sinonasal papillomas JK Stephen et al previously described mathematical algorithm was employed.
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Bisulfite Modification and Methylation-Specific Polymerase Chain Reaction Assay
Genomic DNA (100 ng) from formalin-fixed paraffinembedded papilloma DNA and control universal methylated DNA (Chemicon International Inc., Temecula, CA, USA) and control unmethylated DNA (normal genomic DNA) were modified using the EZ DNA methylation kit (Zymo Research, Orange, CA, USA) during which methylated DNA is protected and unmethylated cytosine is converted into uracil. 19 The modified DNA served as a template using primers specific for either the methylated or the modified unmethylated CDKN2B sequences. CDKN2B methylation-specific primers (MS) were sense: 5 0 -GAAGGTGCGATAGTTTTTGGA AGTCGGCGC, anti-sense; 5 0 -GACGATCTAAATTC CAACCCCGATCCGCCG.
18 Unmethylated DNA-specific primers (UMS) were sense; 5 0 -TGGAGAAGGTG TGATAGTTTTTGGAAGTTGGTGT, antisense; 5 0 -CA TCAACAATCTAAATTCCAACCCCAATCCACCA. 18 MSP amplification was performed using 3 ml of bisulfite-modified DNA in a final volume of 25 ml PCR mix containing 1 Â PCR buffer, 2.5 mM dNTP, 1 mM MgCl 2 and 1 U Amp gold Taq DNA polymerase, 0.5 mM primer followed by 38 cycles at 951C 45 s, 621C 45 s, 721C 1 min. PCR generated a 160 bp methylated product and a 169 bp unmethylated product ( Figure 6 ). The resultant PCR products were separated on 2% agarose gel stained with ethidium bromide and visualized under UV illumination ( Figure 6 ).
Results
All seven cases indicated at least one epigenetic event of aberrant DNA hypermethylation. Ten of the 22 methylation-prone genes indicated promoter hypermethylation ( Table 1 ). The CDKN2B gene was a consistent target of aberrant promoter hypermethylation (Figures 3-5 ) in six of seven cases: three inverted papillomas, two inverted/everted papillomas and one everted papilloma. Methylation-specific PCR confirmed hypermethylation of CDKN2B detected by MS-MLPA in six of seven cases ( Figure  6 ). MSP confirmation for case 7 was not carried out due to insufficient DNA for bisulfite modification and the inability to re-extract additional DNA Figure 4 MS-MLPA probe mix with and without HhaI enzyme (DNA sequencer-ABI 3130). Results for Case 2-biopsy 1 block 6 and biopsy 2 block 2B. Note 15 peaks in the control DNA sample with HhaI. Presence of a peak in biopsies 1 and 2 not present in the control DNA is that of aberrantly methylated CDKN2B gene. Biopsy 2 shows additional peaks for CDKN2A, TP73 and GSTP1, which are not present in the control DNA.
because of depletion of the tissue block. Recurrent biopsies in two inverted papilloma cases had common epigenetic events: aberrant methylation of CDKN2B and DAPK1 in case 1, and CDKN2B in case 2, underscoring monoclonality for these lesions.
Other commonly methylated genes include CDKN2A (2/7), TP73 (2/7), and ESR1 (2/7). TP73 was aberrantly methylated in two inverted papilloma cases. Hypermethylation of ESR1 was observed in one inverted papilloma and one inverted/everted 
Discussion
Inverted papillomas are benign, rare sinonasal lesions well known for their local recurrence, invasiveness and predisposition for malignant transformation. Recurrence rates for inverted papillomas range from 6 to 33% and malignant transformation occurs in 7-10% of cases. 2, 21 Endophytic sinonasal papillomas, comprising inverted papillomas and cylindrical cell papillomas according to the World Health Organization classification, show malignant progression in up to 25% of cases. 22 The exact nature and biological evolution of sinonasal papillomas is not well known. Overexpression of p53 may serve as a marker for malignant transformation of inverted papilloma. 23 Induction of p21waf1/cip1 is associated with terminal differentiation, senescence, and apoptosis in several tissues. 24 Expression of p21waf1/cip1 has been detected in head and neck cancers, in particular oral SCCs and its precursors. 25, 26 Inactivation of a single allele, observed in monoclonal proliferations is usually indicative of a neoplastic process. Inverted papillomas have been shown to be monoclonal proliferations on the basis of X chromosome analysis. 4 Losses at chromosomal arms 3p, 9p21, 11q13, 13q11, and 17p13 occur frequently during neoplastic transformation of the upper respiratory tract. These can be detected in SCCs and the progenitor lesions from which they arise. However, in sinonasal papillomas, loss of heterozygosity at these loci has not been detected. 4 Thus, at the genomic level, inverted papillomas may not routinely harbor several of the key genetic alterations that are associated with malignant transformation.
Promoter methylation-mediated silencing is a hallmark of many established tumor suppressor genes. Aberrant methylation of promoter CpG islands is now recognized as an important mechanism for gene inactivation as an alternative to gene mutation or deletion in tumorigenesis. 27, 28 Hypermethylation of RUNX3, a tumor suppressor gene, was reported in premalignant gastric lesions of chronic gastritis, intestinal metaplasia, and gastric adenomas with a progressive increase in the frequency of RUNX3 methylation in gastric carcinomas. These results suggest that RUNX3 methylation increases with the progression along a multistep gastric carcinogenesis continuum to gastric carcinomas. 29 Epigenetic alterations of promoter hypermethylation have not been previously reported in sinonasal papillomas. Our candidate gene approach using MS-MLPA targeted 22 tumor suppressor genes with known associations to squamous head and neck cancer to investigate whether epigenetic events of promoter hypermethylation might underlie the pathogenesis of sinonasal papillomas.
We observed aberrant methylation at the 9p21 locus for CDKN2B in six of seven and for CDKN2A in two of seven cases. Genetic alterations at the 9p21 locus have been linked to malignant progression in HNSCC. 16, 30, 31 The cyclin-dependent kinase 2A (CDKN2A) and CDKN2B genes map to 9p21 and are in tandem, with CDKN2B located 25 kb centromeric to CDKN2A. 32 The CDKN2A locus controls the Rb pathway (which regulates G1/S-phase transition) and the p53 pathway (which induces growth arrest or apoptosis in response to either DNA damage or inappropriate mitogenic stimuli by generating two gene products). 33 Thus, mutations of CDKN2A/p16 inactivate the Rb pathway, whereas deletions of the CDKN2A INK4a (p16) and CDKN2A ARF (p14) genes alter both the Rb and p53 pathways which are important in many cancers. Cyclin-dependent kinase inhibitor 2B (CDKN2B), which is also known as p15, inhibits CDK4 and regulates cell growth by controlling cell-cycle G1 progression. 34 Inactivation of the CDKN2B (p15) and CDKN2A (p14 and p16) genes at the genomic and epigenetic level is a frequent event in human oral SCCs and in HNSCC. 12, 14, 35 One study reported aberrant methylation of CDKN2B (p15) and CDKN2A (p16) in more than 50% of the oral SCCs. 36 The presence of aberrant methylation of p15 and p16 in precancerous oral tissues 35 implicates methylation of p15 and p16 as early events in the pathogenesis of oral lesions. In undifferentiated nasopharyngeal carcinoma (NPC), preferential methylation of CDKN2B has been shown to be a useful tumor marker for NPC. 37 Other commonly methylated genes include TP73 (2/7 cases) and ESR1 (2/7 cases). TP73, located at 1p36.3, is involved in cell-cycle regulation, and is frequently deleted in many types of human tumors. [38] [39] [40] TP73 codes a product which has significant structural homology to the TP53 gene product in the domains involving transactivation, DNA binding and oligomerization. 41 Functionally, the TP73 gene product is able to activate the TP53-responsive proteins, inhibit cell growth and induce apoptosis. 42 Hypermethylation of TP73 in NPCs has been reported with a frequency of 20%. 37 In head and neck SCC, hypermethylation of TP73 occurred as a primary as well as a disease progression event. 12 Estrogen receptor 1 (ESR1), maps to 6q25.1 and is important for hormone binding, DNA binding, and activation of transcription. 43 ESR1 has metastasissuppressor properties in breast cancer cells, 44 suggesting a tumor-suppressor role for ESR1.
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ESR1 is methylated in Barrett's metaplastic and dysplastic samples and in some adenocarcinoma samples. In esophageal adenocarcinomas, abnormal methylation patterns were found in premalignant Barrett's tissue in addition to adenocarcinoma tissue suggesting that DNA hypermethylation is an early epigenetic event in the progression of esophageal adenocarcinomas. 46 Of the two cases where ESR1 was methylated in our cohort, one was an inverted papilloma and the other an inverted papilloma/ everted papilloma.
Our novel genome-wide strategy identified several genes with aberrant promoter hypermethylation. Recurrent genomic aberrations are good indicators of genes that are causally associated with cancer development or progression and either become or reveal gene targets for therapy. Frequently, methylated genes in this sinonasal papilloma cohort included CDKN2B, CDKN2A, TP73, and ESR1.
In this sinonasal papilloma cohort, the CDKN2B gene, a chromosome 9p21 locus resident was a common epigenetic target. Persistence of aberrant hypermethylation of common epigenetic events in recurrent biopsies (cases 1 and 2) underscored a monoclonal origin for inverted papilloma. These findings support a role for epigenetic events of promoter hypermethylation in the pathogenesis of benign inverted and exophytic papillomas. As a consistent target of aberrant promoter hypermethylation, CDKN2B may serve as a useful biomarker and a potential therapeutic target for gene reactivation studies and in disease monitoring for progression, similar to serum SCC antigen level monitoring of inverted papilloma status. 47 In the latter, serum SCC antigen levels in patients with gynecologic, head and neck, lung, and esophageal SCCs are elevated and it has been widely used as a tumor marker with the potential for monitoring the course of disease.
Promoter methylation-mediated silencing is a hallmark of many established tumor suppressor genes. An important distinction between genetic and epigenetic changes in cancer is that the latter might be more easily reversed using therapeutic interventions. Because gene silencing, as a consequence of promoter hypermethylation, can be partially relieved by demethylation of the promoter region, 27, 28 the molecules that regulate methylation status of DNA are considered promising targets for new cancer therapies. Identifying epigenetic alterations in benign sinonasal papillomas may lead to the discovery of biomarkers that aid in the diagnosis and prognosis of sinonasal papillomas.
